Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Evaluation of OraFID Dispenser and App for Flexilev in Parkinson's Disease
2025-524296-23-01Phase 4Authorised
- Sponsor
- Navamedic ASA
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carbidopa + levodopa in Parkinson's disease (PD), sponsored by Navamedic ASA. Primary endpoint: Patient-reported evaluation of OraFID device. Planned start Feb 2026; status: authorised.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-524296-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524296-23-01.